Drug Interaction Report

MONITOR CLOSELY: The concomitant use of aldesleukin and interferon alfa may increase the risk of severe rhabdomyolysis and myocardial injury, including myocardial infarction, myocarditis and ventricular hypokinesia. In addition, the use of sequential high-dose aldesleukin and interferon alfa has been associated with hypersensitivity reactions requiring medical intervention. Symptoms occurred within a few hours after administration and included erythema, pruritus, and hypotension.

MANAGEMENT: Caution and close clinical and laboratory monitoring for signs and symptoms of toxicity and hypersensitivity reactions is advisable.

ADJUST DOSING INTERVAL: Food enhances the oral absorption and bioavailability of ribavirin. Administration of a single oral dose of ribavirin following a high-fat meal delayed absorption (Tmax was doubled) but increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by up to 70% compared to administration in the fasting state.

MANAGEMENT: To ensure maximal oral absorption, ribavirin should be administered with or immediately after a meal.